The in vitro stimulation of T lymphocytes is frequently used as a technique to expand specific cells present at low precursor frequency in vivo. However, cells analysed after such procedures may no longer reflect those originally present in vivo because of the variable efficiency of outgrowth of different T cell subpopulations. To systematically assess this and to complement functional assays, we have analysed the TCR repertoire using a new high resolution RT-PCR method to determine TCR β chain CDR3 transcript length. In the ex vivo analysis of tumor infiltrating lymphocytes (TIL) of renal cell carcinoma and glioblastoma patients, we observed and quantified oligoclonally expanded populations of T cells that were very susceptible to repertoire modification upon subsequent in vitro culture with autologous tumor cells. This in vitro repertoire skewing occurred preferentially with TIL rather than peripheral blood lymphocytes and we noted that tumor cells rather than normal cells of the same tissue type were the most potent inducers of the effect. It was striking that this selection was sometimes negative: certain prominent T cell populations that were highly represented in vivo disappeared after in vitro re-stimulation. This suggests that the presentation of tumor associated antigens during culture may eliminate rather than enrich for in vivo primed T cells. It is clear that in vitro functional tests cannot adequately describe all T cells with tumor specificity. Approaches that allow the assessment of potentially antigen-reactive T cell populations ex vivo are thus an important advance in the global appraisal of anti-tumor T cell immune responses.
Introduction
T cell recognition of specific antigens restricted by MHC class characterization of tumor-specific T cells (1), but has certain limitations. It probably underestimates the overall anti-tumor I and class II molecules has generally been investigated using in vitro functional tests such as proliferation, cytotoxicity T cell response because T cells (particularly those infiltrating tumors) may have low proliferative potential (2), impaired or cytokine release. However, such tests rely on (i) the availability of antigen (or cells expressing the antigen), (ii) a cytolytic function (3) and defects in cytokine production (4) or could possibly be in an anergic state. Furthermore, in frequency of specific T cells appropriate for the sensitivity of the test and (iii) cells that are functionally competent in vitro.
situations where purified antigens are not available (i.e. in most tumors), the tumor cells used for stimulating T cell Such conditions are not always met from T cell populations isolated ex vivo and in vitro expansion or re-stimulation is cultures may not adequately present the putative antigens due to low or absent MHC expression (5-7), specific antigen thus frequently utilized. In the case of anti-tumor immune responses, mixed lymphocyte tumor cell culture (MLTC) is loss (8), low antigen density (9,10) or defects in antigen processing (11). used to expand tumor cell-specific T cells in an in vitro environment that minimizes the immunosuppressive condiIn order to better assess the overall anti-tumor T cell response, we have taken advantage of a new high-resolution tions that may have been originally present in vivo. This in vitro approach has sometimes led to the successful RT-PCR method based on the determination of the TCR β chain CDR3 transcript length (12,13). This technique is sensitive 10 5 tumor cells in the presence of 10 6 irradiated LAZ 509 (Epstein-Barr virus-transformed cell line). Two stimulations at enough to detect T cell clonal expansions in vivo, without the necessity of functional tests and in vitro culture. Recurrent weekly intervals were performed (20-to 50-fold expansion between stimulations). For the second RCC patient, coidentical size transcripts are found after specific T cell clonal expansion in response to defined antigens (12) (13) (14) . Their cultures of TIL were performed either with tumor cells or with normal renal cells, using the same conditions described presence in tumor infiltrating lymphocytes (TIL) may thus reflect the response driven by putative and still undefined above. T cells derived from glioblastoma were cultured in Iscove's antigens. Indeed, we demonstrated that in certain cases, the T cell populations detected in vivo by these molecular methods medium (Gibco/BRL) supplemented with 10% human serum and 30 U/ml rIL-2 to establish the TIL lines. Two re-stimulations could be expanded in vitro and were tumor specific in cytotoxicity assays (15).
were carried out at~3 week intervals using allogeneic irradiated PBMC and 1 µg/ml purified phytohemagglutinin (Murex In this study, we show that some significant clonal expansions detectable in vivo are lost after in vitro culture and that, Diagnostics, Dartford, UK), and then a second MLTC (considering the first 3 days of culture to be the first MLTC) was furthermore, the fate of such populations is dependent upon the nature of the stimulating cells. Our results suggest that carried out using 10 5 T cells with 10 4 autologous tumor cells (10-to 40-fold expansion between stimulations). MLTC procedures utilized to expand antigen-specific T cells may instead induce the selective depletion of potentially Flow cytometry antigen-reactive populations. Previous studies based on ex vivo phenotypic analysis of antigen-selected cells that express T cell populations and tumor cell lines were analysed on a FACScan equipped with Lysys II software, calibrated by eye distinctive TCR also indicated that functional assays underestimate the real T cell response (16 HLA class I and class II gene products respectively. Staining were processed immediately after removal at surgery to obtain was revealed with a FITC-conjugated goat anti-mouse Ig single-cell suspensions using enzymatic digestion. Briefly, (Immunotech). All analyses were performed after gating on tissue was enzymatically digested for 1-2 h at 37°C in culture viable lymphocyte populations using a combination of forward medium containing 0.1% collagenase type IA, 0.002% DNase and side light scatter (linear amplification). type II and either 0.001% hyaluronidase (for RCC) or 0.05% TCRBV gene segment usage protease type I (for glioblastoma). The resulting cell suspensions were centrifuged over a Ficoll-Hypaque gradient (Phar-TCRBV gene segment usage was determined by RT-PCR as macia, Uppsala, Sweden) and then cultured in DMEM medium previously described (18) . Briefly, total RNA was prepared containing 10% FCS. All enzymes were obtained from Sigma from tumor, lymph nodes, PBL and MLTC (0.2-0.5 g tissue (St Louis, MO) and media were from Gibco/BRL (Life Technoloor 2-5ϫ10 6 cells) using TRIzol (Gibco/BRL) and converted gies, Paisley, UK). From one RCC patient, a normal kidney to cDNA by standard methods using reverse transcriptase cell line that expanded for five passages was also obtained and an oligo d(T) primer. These cDNAs were amplified in using the same techniques.
non-saturating PCR conditions with a panel of experimentally validated 5Ј sense primers specific for the 24 BV subfamilies Isolation and culture of T cells and one 3Ј antisense primer for the BC gene segment. The specificity of the amplified products was assessed after T cells were either obtained from digested tumor tissue as described above (i.e. TIL), from tumor draining lymph node Southern blotting and hybridization with a labelled BC oligonucleotide, and also by verifying the length of the PCR products (TLN) which was also digested in the same way or from peripheral blood lymphocytes (PBL) obtained after Ficollwith values deduced from the BV1-24 and BC primer positions. The comparative analysis of each BV product between Hypaque centrifugation. For glioblastoma, non-adherent cells were taken from the tumor cell cultures described above after the different samples was achieved by densitometric analysis of the signals on the autoradiographs. 3 days of culture.
For RCC patients, TIL and cells from TLN were expanded CDR3 size analysis of TCRBV transcripts for 6 days prior to MLTC in RPMI 1640 with 10% human serum, 10 U/ml rIL-2 and 3% conditioned medium from The CDR3 region of the PCR-amplified TCRBV1-24 transcripts was analysed using a run-off procedure, as previously phytohemagglutinin-activated lymphocytes. PBL were not expanded before MLTC. In MLTC for the first patient, 3-5ϫ10 5 described (12,13). Briefly, aliquots (2 µl) of the BV1-24/BC PCR products (40 cycles) were subjected to one to three T cells (from TIL, TLN and PBL respectively) were mixed with cycle run-off reactions, using dye-labelled oligonucleotide primers, specific either for BC or one of the 13 human functional BJ segments. The run-off products were then run on an automated sequencer in the presence of fluorescent size markers. The length of the DNA fragments and the fluorescence intensity of the bands were analysed with Immunoscope software (developed by C. Pannetier) or Genescan Analysis software (Applied Biosystems, Forster City, CA). Hilden, Germany) and sequenced using the Dye Terminator Cycle Sequencing Kit (ABI PRISM; Perkin Elmer, Forster City, CA) according to the manufacturer's instructions.
Sequencing of PCR products
samples (RNA directly analysed ex vivo), and compared Quantification of clonal expansions in glioblastoma samples these to the corresponding T cells after various periods of in vitro culture. To quantify the respective proportions of recurrent BV13 transcripts in the total BV13 mRNAs (Fig. 6) , clonotypic TCR repertoire of TIL analysed ex vivo is dramatically altered primers hybridizing with the CDR3 region of the recurrent after in vitro culture with autologous tumor cells BV13 sequences from TIL ex vivo or after MLTC were synthesized and labelled with a 6-Fam fluorophore (GENSET, Paris, TIL, TLN and PBL from RCC patient 1 were stimulated twice at weekly intervals using autologous tumor cells. Using RTFrance). Primer sequences were 5Ј-AGCTCCCCGGTGT-TCGGGAGT-3Ј for the recurrent cDNA clone detected in TIL PCR, we analysed the BV gene usage in MLTC-derived T cell lines and compared it to that observed ex vivo from tumor, ex vivo (CDR3-ex vivo primer) and 5Ј-CTGCTCATTGTAA-GTCCTCCA-3Ј for the recurrent cDNA clone detected in TIL TLN or PBL. The amplified material was revealed by autoradiography. Results for TIL analysed ex vivo, after 6 days in after MLTC (CDR3-in vitro primer). Samples were amplified using a BV13 and a BC primer, then aliquots of BV13-BC culture with low-dose IL-2 alone or after MLTC are shown in Fig. 1 . Each TCRBV gene product was obtained with the PCR products were subjected to an elongation with either a 6-Fam-labelled and nested BC primer (13) or with one of the expected size (deduced from the positions of the TCRBV and TCRBC primers on cDNA sequence), varying from 250 to 535 two clonotypic primers. The two run-off products were loaded in equal amounts in the automated sequencer. The proportion bp. Autoradiographs were analysed by densitometry which allows the comparison of the usage of a given BV gene in of the specific sequence in the total BV13 mRNA population was then calculated by dividing the area under the curve the different samples, since the same primer pair was used in the PCR reactions (Fig. 2 ). The repertoire of T cells from (AUC) obtained with the clonotypic primers by the sum of the AUC obtained with the BC primer. This calculated ratio was uncultured PBL and TLN was diverse with almost all BV genes expressed, whilst T cells present within tumor displayed a then corrected by the relative specific activity of the clonotypic primers (see legend of Fig. 6 ). With the exception of sequenrestricted BV gene usage, with particularly abundant BV4 transcripts. In addition, the repertoire of PBL and TLN was cing, all molecular experiments were performed at least twice, with highly reproducible results.
not significantly modified by co-culture with autologous tumor cells. Indeed, the variation of the relative expression of any of the BV gene segments did not exceed the mean value Results Ϯ 1 SD (20) . In contrast, the same in vitro procedure induced major modifications of the BV gene usage in cultured TIL In previously published studies (15, 19) , the in vivo repertoire in RCC and the representation of a specific cytotoxic T when compared with the ex vivo TIL repertoire, with a major increase in BV14, BV16 and BV17 expression, and a dramatic lymphocyte (CTL) clone was analysed. Here, we extend these studies, to more globally and systematically analyse T cell decrease in BV4 expression (Figs 1 and 2). We also used TCRBV-specific mAb and flow cytometric anarepertoires in vivo and after in vitro culture. In particular we wished to address whether commonly used in vitro culture lysis to confirm the results of the molecular analysis, and observed similar striking differences between the different techniques always achieve the usual aim of expanding in vivo primed T cells. To circumvent the problem of non-detection co-cultures. In TIL after MLTC (comprising 92% CD3 ϩ cells), 45, 32 and 7% of lymphocytes were labelled with mAb to of T cells without function in in vitro tests (or of cells that showed no further expansion in vitro), we used sensitive BV14, BV17 and BV16 respectively, whereas BV13 (mAb BV13S3 ϩ BV13S6) T cells constituted Ͻ1.5% of the cells RT-PCR based methods of the TCR repertoire to analyse oligoclonal expansions of T cells. We have analysed blood (Fig. 3) . In contrast, none of these BV-specific mAb labelled Ͼ6% TLN lymphocytes in MLTC (data not shown). These (after Ficoll-Hypaque isolation) and unmanipulated tissue by run-off analysis of RCC samples (Fig. 4) . BV-BC products were copied with a nested fluorescent BC and the sizes of the fluorescent run-off products were determined by electrophoresis on an automated DNA sequencer. Size variations of the run-off products are strictly due to different CDR3 lengths reflecting the imprecise V-D-J joining mechanism. In PBL of healthy donors, the repertoire of any BV-BC and BV-BJ combination usually displays a bell-shaped profile with 3-nucleotide-spaced peaks corresponding to in-frame sequences (13,21). In contrast, the emergence of one dominant peak reveals the presence of cDNAs with identical or same size in frame junctional regions.
Several observations can be made from these data. Some dominant peaks observed ex vivo disappeared or were significantly diminished after in vitro culture (Fig. 4) . The BV4 transcripts, highly expressed in the ex vivo sample, contained one major peak corresponding to a CDR3 size of 10 amino acids (Fig. 4a ). After MLTC (Fig. 4b) , TIL BV4 transcripts contained a prominent peak not detected ex vivo (CDR3 size of 5 amino acids) and a weaker peak (CDR3 size of 10 amino acids) matching the main peak detected ex vivo. These data support the view of a counterselection of an in vivo expanded T cell population (with a 10 amino acid CDR3 size) during in vitro culture. Similarly, the intense peak (consistent with the expansion of T cells bearing a CDR3 of 8 amino acids) observed ex vivo in BV13 was not detectable after MLTC, whereas a peak corresponding to T cells with a 10 amino acid CDR3 size clearly emerged. The shift in the principal BV16 peaks (9 amino acids in ex vivo TIL sample versus 8 amino acids after MLTC) is an additional example (Fig. 4) .
However, MLTC is clearly useful in some cases to facilitate the in vitro outgrowth of T cell populations that are detectable in ex vivo samples, but which do not represent major peaks. For example, BV17 ϩ T cells with CDR3 sizes of 10 or 11 amino acids that were present in the ex vivo tumor sample (but were not the predominant peaks) became the major populations after MLTC (Fig. 4) . Furthermore, we have previously reported that one of these two peaks corresponded to a tumor cellspecific CTL clone obtained after direct cloning of TIL [(15), lower frequency of tumor-specific T cells among PBL compared with TIL. The situation with TLN ( Fig. 4d) was intermediate between that of PBL and TIL, with some polyclonal patterns conserved (e.g. BV4), but certain prominent peaks showing phenotypic data support the conclusion from the molecular analysis, i.e. there are high proportions of BV14, BV16 and significant in vitro selection (e.g. BV17). BV17 T cells after in vitro stimulation with autologous tumor cells.
In vitro skewing occurs after culture of T cells infiltrating different tumor types Oligoclonal TIL and TLN populations are subject to greater in vitro selective pressure than PBL To see whether skewing phenomena were restricted to RCC, the TCR repertoire of T cells from human glioblastoma was also To assess the putative clonality of expanded T cells subsets in TIL after MLTC and their representation in vivo, we examined investigated. The BV gene segment usage of TIL after MLTC (10 days after the last addition of tumor cells and 50 days after the CDR3 size distribution of the corresponding BV transcripts the beginning of culture) was studied and compared with that compared with PBL (22 and Dietrich et al., manuscript in preparation). In the glioblastoma patient analysed here (Fig. 5) , the observed in T cells ex vivo (tumor biopsy and PBL RNA: Fig. 5 ). Here again, some BV specificities highly expressed in relative expression of TCRBV13 transcripts was significantly higher in TIL ex vivo than in PBL. After subsequent in vitro culture TIL ex vivo disappeared after in vitro co-culture with autologous tumor cells (e.g. BV4, BV5, BV6 and BV15). In contrast, some of TIL, the TCRBV13 was the most abundantly expressed BV. Indeed, we confirmed the representation of BV13 ϩ cells in the BV specificities such as BV12 and BV16 poorly represented in the ex vivo sample gave rise to significant proportions of the T cultured TIL by flow cytometry, which revealed Ͼ70% of total T cells reacting with mAb specific for BV13S1 and BV13S2 (data cell repertoire after in vitro culture. A further category can be considered: BV families that were highly represented when not shown). We therefore assessed whether the BV13 T cells expanding after in vitro stimulation with autologous glioma cells analysed ex vivo showing further expansion in vitro (e.g. BV13 and BV14). Of these subsets, BV13 ϩ T cells are of particular were the same as those overexpressed in vivo. The run-off procedure was used to define the CDR3 size interest, since this BV is frequently overexpressed in glioma Fig. 6(A) . Clonotypic primers specific for the CDR3 region of both recurrent sequences were synthesized (CDR3-ex vivo and CDR3-in vitro primers: Fig. 6B ). To determine the proportion of the BV13S2-BJ2S2 and BV13S1-BJ2S1 clones in the total BV13 population present in TIL ex vivo or in TIL after MLTC, the BV13-BC PCR products were copied with the labelled BC primer, the CDR3-ex vivo primer or the CDR3-in vitro primer and their CDR3 size distribution was analysed in the automated sequencer. The BV13S2-BJ2S2 clone represented 25% of the total BV13 mRNAs in the ex vivo sample (after correcting for the specific activity of the CDR3-ex vivo primer), but was undetectable in TIL after MLTC (Fig. 6C) . Thus, this highly expanded clone that we estimate to represent~4% of total T cells ex vivo (Figs 5 and 6) was eliminated in culture. On the other hand, the BV13S1-BJ2S1 clone remained undetectable in the ex vivo sample, whereas it was highly expressed in TIL after MLTC, representing 85% of the BV13 transcripts. Therefore, since the In vitro skewing is most pronounced when tumor cells rather (Fig. 6A) . At a first level of analysis using the fluorescent BC than normal cells of the same lineage are used for in vitro primer, we observed that the BV13-BC PCR products from the stimulation ex vivo tumor sample displayed a nearly bell-shaped pattern with, however, two slightly prominent peaks corresponding to Whilst TIL (rather than PBL) from different tumors were clearly susceptible to in vitro skewing, we wanted to determine if this T cells bearing β chains with CDR3 sizes of 8 and 9 amino acids respectively. In the cultured TIL, a single peak (CDR3 of 8 amino was an intrinsic property of TIL in culture or whether different stimulator cells influenced this selection to a greater or lesser acids) was highly predominant. To further characterize the BV13 transcripts with the same size CDR3 (8 amino acids), extent. We therefore compared the CDR3 profiles in three different cultures from another RCC patient: TIL cultured in the pres-BV13-BC PCR products were copied with the 13 BJ primers. Each BV13-BJ profile of the tumor sample analysed ex vivo ence of IL-2 (Fig. 7a) , TIL stimulated by autologous tumor cells (Fig. 7b) and TIL stimulated by autologous normal kidney displayed several peaks corresponding to transcripts of different CDR3 sizes, often with an fluorescence intensity close to cells (Fig. 7c) . The representative profiles of BV-BC PCR products shown in Fig. 7 indicate that the co-culture of TIL with tumor background levels (data not shown). The single exception was the BV13-BJ2S2 profile where an intense and prominent peak cells induced a major restriction of the number of T cell clones within a given BV specificity, whilst no obvious difference was corresponding to a CDR3 size of 9 amino acids was noted. In contrast, no BV13-BJ2S2 amplified transcript was detected in observed following co-culture with normal kidney cells. These results are consistent with tumor cell-specific signals to in vivo TIL after MLTC, but a significant peak (CDR3 size at 8 amino acids) was seen in the BV13-BJ2S1 profile. Therefore, despite primed TIL that can act either in a positive (in vitro selection and growth) or a negative (inhibition of growth) manner. Unlike overexpression of BV13 T cells both in vivo and after in vitro culture, analysis of CDR3 size shows that the prominent BV13-some tumor cell lines that are low or negative for MHC expression, the three tumor cell lines used for this study are MHC class BJ2S2 T cell population detected in the ex vivo sample did not expand in vitro, whereas the BV13-BJ2S1 T cells proliferating I ϩ (Fig. 8) and thus may potentially present antigens to class Irestricted CD8 T cells. Since MHC class II is not constitutively in vitro probably derive from minor in vivo populations.
expressed (Fig. 8) , the repertoire selection could thus be more
Quantification of individual clones ex vivo and after MLTC
pronounced for the CD8 ϩ T. However, we cannot exclude that cytokines secreted in the culture microenvironment may lead To quantify the extent of in vitro skewing, random sequencing of BV13-BC PCR products was used, leading to the identificato the transient expression of MHC class II molecules, since class II expression was inducible by IFN-γ on the three cell lines tion of BV13 clones that were highly represented either in TIL ex vivo or in TIL after MLTC. A recurrent BV13S2-BJ2S2 sequence (data not shown). (four of eight sequences) with a CDR3 size of 9 amino acids was found in the ex vivo sample and a different recurrent Discussion BV13S1-BJ2S1 sequence (nine of 11 sequences) with a CDR3 size of 8 amino acids was found in TIL after MLTC (Fig. 6B) .
Whilst high efficiency culture of normal human T cell populations (e.g. from PBL) is possible (23) , the general experience These data are consistent with the CDR3 profiles shown in with T cells derived from cancer patients is of a much reduced during culture. These results are thus not only descriptive of specific T cell populations, but are also predictive of TCR with clonogenic potential, particularly from TIL (2,24). Is this just because there is global immunosuppression affecting all T cells potential antigen reactivity. Such predictions may therefore be exploitable for the subsequent isolation of T cell populations or are more specific inhibitory interactions in operation? This is an extremely difficult question to answer using traditional enriched for antigen specificity, as demonstrated in a case of chronic lymphocytic leukaemia (25) . These approaches may techniques to assess immune function and specificity, since only those cells that actually expand in vitro are testable. In an be further refined by selecting subsets defined by other phenotypic markers (16) . attempt to partially circumvent this technical limitation and to thus better define the overall anti-tumor immune response, we Several features emerge from the present study. When lymphocyte populations were first analysed ex vivo, we have exploited the high resolution properties of the analysis of CDR3 transcript length within ex vivo and in vitro populations observed a higher representation of oligoclonal T cell populations in TIL and to a lesser extent in TLN (i.e. those compartdefined for both BV and BJ usage (13). This technique generates data that reveal highly distinctive profiles corresponding ments in closest proximity to the tumor) compared with blood. However, the major finding of this study is that in vitro culture to either polyclonal or oligoclonal T cell expansions. This has enabled us to identify T cell populations that were probably dramatically skews the representation of different T cell populations compared with their starting proportions. Whilst this was selected by antigen in vivo and to follow their fate systematically a role of tumor-associated antigenic stimulation in this skewing, causing either in vitro expansion or elimination of T cells that were presumably primed in vivo. In our quantitative analysis we showed that MLTC can substantially expand clones poorly represented in vivo, which for one clone we estimated to be a 62,000-fold enrichment. Conversely, a major clone that we estimated to represent 4% of TIL in vivo disappeared after MLTC (Fig. 6) . If the loss of oligoclonally expanded T cell populations is a specific effect, these eliminated populations warrant as much attention as T cell populations that actually proliferate in culture.
The ex vivo identification of T cell populations that subsequently exhibit highly diverse growth patterns during culture raises questions about their functional status at the outset. The cells that do expand in vitro are presumably in a primed state, referred to as BV19 in this previous report according to old nomenclature]. In a case of a regressive melanoma, there is evidence that in vitro growth patterns may also depend upon T cell interactions. The growth of one CTL clone (BV13) with specific anti-tumor activity was achieved after MLTC, whereas another clone (BV16) with a higher representation in vivo could be cultured only after sorting, rather than as a bulk T cell line (26, 27) . Utilization of BV specific mAb for sorting is not always feasible since many specificities are not available and, furthermore, crude BV usage may not always provide sufficient enrichment for specific cells, as shown with our more refined analyses based on CDR3 size. However, it is clear that expression of an appropriate receptor for antigen recognition and in vitro growth are not sufficient conditions to ensure specific effector function. This may be due to selective defects in cytokine production (4) or impaired cytolytic function (3). Thus, we cannot exclude that, for example, the BV14 ϩ expanded T cells from RCC TIL (Figs 1-4) may be antigen specific, despite lack of specific cytolytic properties (15). Diminished or incomplete effector functions may be a consequence of immunosuppressive cytokine secretion in the tumor microenvironment, such as transforming growth factor-β or IL-10 (28-34), or by the expression of FasL on the tumor cell surface (35) (36) (37) (38) . Alternatively, inadequate expansions observed ex vivo in RCC (19) and glioblastoma (22) , and also in other malignancies (25, 46) , but the lack of spontaneous tumor rejection in most cases.
It is clear from some experiments that certain T cells poorly partly anticipated (since the principal objective of in vitro stimulation is to enrich for antigen specific cells), TCR analysis represented in vivo strongly expand in vitro. This may reflect the growth of tumor antigen-specific cells now able to proliferate revealed that this in vitro selection was far from uniform. In particular, it was the highly oligoclonal TIL that were the most in the absence of the immunosuppressive conditions that were present in vivo: these cultures therefore achieve one of the susceptible to repertoire modifications in vitro, especially after culture with tumor rather than normal cell lines. Indeed, the principal goals of MLTC. Indeed, the in vitro expansion of CTL precursor cells has successfully led to the identification of the tumor cell lines studied here all expressed MHC molecules (constitutive for class I, inducible for class II), and thus are majority of tumor-associated antigens characterized to date. However, caution must be exercised in interpreting in vitro potential antigen-presenting cells (APC). This is consistent with when assessed by cytotoxicity assays alone has been sug-6 Dhib-Jalbut, S., Kufta, C. V., Flerlage, M., Shimojo, N. and gested in independent studies using different approaches. In 
